Roche has entered into a licensing partnership with Sarepta Therapeutics worth USD 1.15 Billion. Roche has agreed to license in Sarepta’s gene therapy ‘SRP-9001’ for Duchenne muscular dystrophy (DMD), though which Roche will gain access to exclusive rights to it globally except in the US. As per t...
Find MoreMerck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay USD 20 for each share in cash for a total amount of USD 2.7 Billion. ArQule is a biopharmaceutical, which is focused on kinase inhibitor discovery, finding cures for cancer p...
Find MoreWhen cough seems everlasting, mortifying, and excruciating, it is high time to consult a physician as you might be stricken by chronic cough, which can be irritating and may also lead to nagging cough and a throbbing headache. Although chronic cough is not usually severe, it can be very annoying. Chronic Refractory...
Find MoreMore than a dozen companies have shifted their focus towards the Hormone Receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer therapeutic area. Some of them are Jiangsu HengRui Medicine Co., Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Roche Group Syndax Ph...
Find MoreHormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer is the most prevalent form of breast cancer. This type accounts for a higher percentage among all breast cancers. Hormone receptors are proteins that receive hormone signals and cue the cancer cells to grow. If breast cancer ce...
Find MoreBreast cancer is not a single disease leading to abnormal cell division in breast tissues. In the United States, it is estimated that more than 40,000 women will die from breast cancer in 2017. According to DelveInsight’s estimates, the total Breast cancer incident population in the 7MM was found to be 626,867 in 2...
Find MoreThemis Bioscience forms an Exclusive License and Research Alliance with MSD to Develop Vaccines Themis Bioscience, a vaccine development firm, has collaborated with the MSD, a trademark company of the Merck. The agreement is an exclusive license with MSD for the discovery and development of measles vaccines to f...
Find MoreTelegenomics Company Genome Medical nets USD 23 M Genome Medical, a telegenomics company, having expertise in delivering genome-based medicine has raised USD 23 Million in series B funding. The proceeds will be used by the company to accelerate the development of its technology and medical services to supp...
Find MoreMerck decides to acquire Peloton Therapeutics, fortifying Oncology pipeline Merck is ready to buy Peloton Therapeutics for USD 1.1 million. The companies have entered into a definitive agreement which will give Merck rights over an oral HIF-2α inhibitor- PT2977, which is Peloton’s lead candidate for the treatme...
Find MoreEISAI now solely responsible for lemborexant Eisai today announced that its U.S. subsidiary has bought out Purdue Pharma L.P.’s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multip...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.